Patrice Olson | Authors


Biomarkers at 12 Weeks Predict Prognosis in mCRPC at 2 Years

December 05, 2013

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.